Abstract
Background
The cancer is serious health problem and leading cause of death in the world.
Area covered
There have intensively studied for diagnosis and therapy of this disease and these studies provided important insights into their mechanism of action and therapeutic/diagnostic effects. The accurence rates of cancer has dramatic increase, particularly in the developed countries. Although there are many different strategies about diagnosis and treatment for cancer, more effective new approaches are needed.
Expert opinion
In this review, we summarize recent developments on cancer diagnosis, radiopharmaceuticals in cancer diagnosis, nanoparticulate systems in cancer diagnosis, T cells in cancer diagnosis, cancer therapy and pharmacokinetic of anticancer drugs. We thought that while there are some current limitations such as clinical studies, ranging from diagnosis to theraphy, future improvements in cancer diagnosis and treatment will meet the most relevant issues required for the eventual approval of nano-drugs, radiopharmaceuticals, T cells in clinical practice.
Similar content being viewed by others
References
Ahearne MJ, Bhuller K, Hew R, Ibrahim H, Naresh K, Wagner SD (2014) Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma. Virchows Arch 465(3):351–358
Al-Saeedi F (2002) Role of 99mTc-(V)DMSA in detecting tumor cell proliferation. Anal Chem Insights 2:81–83
Arnold PY, Davidian DK, Mannie MD (1997) Antigen presentation by T cells: T cell receptor ligation promotes antigen acquisition from professional antigen-presenting cells. Eur J Immunol 27(12):3198–3205
Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M et al (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14(10):3044–3051
Boyle P, Levin B (2008) World Cancer Report 2018. IARC Press, International Agency for Research on Cancer. World Health Organization, Lyon, p 510
Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54(5):631–651
Cegnar M, Premzl A, Zavasnik-Bergant V, Kristl J, Kos J (2004) Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. Exp Cell Res 301(2):223–231
Chakravarty R, Hong H, Cai W (2014) Positron emission tomography image-guided drug delivery: current status and future perspectives. Mol Pharm 11(11):3777–3797
Chakravarty R, Hong H, Cai W (2015) Image-guided drug delivery with single-photon emission computed tomography: a review of literature. Curr Drug Targets 16(6):592–609
Chernov VI, Triss SV, Skuridin VS, Lishmanov YB (1996) Thallium-199: a new radiopharmaceutical for myocardial perfusion imaging. Int J Cardiac Imaging 12(2):119–126
Chernov V, Rogov A, Skuridin V, Stasyuk E, Nestrow E, Varlamova N, Zelchan R et al (2015) Eur J Nucl Med Mol Imaging 42(1):498
Chernov V, Bragina O, Sinilkin I, Medvedeva A, Zelchan R (2016) Vestnik Rentgenologii Radiologii 97(5):306–313
Chiriva-Internati M, Grizzi F, Pinkston J, Morrow KJ, D'Cunha N, Frezza EE, Muzzio PC et al (2006) Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. Vitro Cell Dev Biol Anim 42(3–4):89–95
De Charette M, Marabelle A, Houot R (2016) Turning tumour cells into antigen presenting cells: the next step to improve cancer immunotherapy? Eur J Cancer 68:134–147
Destito G, Yeh R, Rae CS, Finn MG, Manchester M (2007) Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chem Biol 14(10):1152–1162
Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL et al (2009) Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 27(28):4685–4692
Dominguez-Gil Hurle A. (2006) Farmacocinética de los medicamentos obtenidos por biotecnología. In: Bueren J, Motellon JL (eds.). Curso de Biotecnología Aplicada. 6th edn. CIEMAT, Madrid; pp 121–34. https://www.sefh.es/bibliotecavirtual/biotecnologia/10farmacocinetica.pdf
D'Souza MM, Sharma R, Tripathi M, Panwar P, Jaimini A, Mondal A (2011) Novel positron emission tomography radiotracers in brain tumor imaging. Indian J Radiol Imaging 21(3):202–208
Garattini S (2007) Pharmacokinetics in cancer chemotherapy. Eur J Cancer 43(2):271–282
Good Practice for Introducing Radiopharmaceuticals for Clinical Use IAEA TECDOC IAEA-TECDOC (1782).
Griesser H, Mak TW (1994) The T-cell receptor–structure, function, and clinical application. Hematol Pathol 8(1–2):1–23
Hadrup S, Donia M, Thor SP (2013) Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron 6(2):123–133
Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST (2017) Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev 108:25–38
Herrmann F, Lehr HA, Drexler I, Sutter G, Hengstler J, Wollscheid U, Seliger B (2004) HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 64(1):215–220
Inoue M, Mimura K, Izawa S, Shiraishi K, Inoue A, Shiba S, Watanabe M et al (2012) Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology 1(7):1104–1110
Kim MS, Hwang SJ, Han JK, Choi EK, Park HJ, Kim JS, Lee DS (2006) pH-responsive PEG-poly (b-amino ester) block copolymer micelles with a sharp transition. Macromol Rapid Commun 27(6):447–451
Kundu M, Sadhukhan P, Ghosh N, Chatterjee S, Manna P, Parames C (2019) pH-responsive and targeted delivery of curcumin via phenylboronic acid-functionalized ZnO nanoparticles for breast cancer therapy. J Adv Res 13:24–67
Kunjachan S, Ehling J, Storm G, Kiessling F, Lammers T (2015) Noninvasive imaging of nanomedicines and nanotheranostics: principles, progress, and prospects. Chem Rev 115(19):10907–10937
Lakna P. (2017) Difference between humoral and cell mediated immunity. Human Anat. https://pediaa.com/difference-between-humoral-and-cell-mediated-immunity/
Lammers T, Kiessling F, Hennink WE, Storm G (2010) Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm 7(6):1899–1912
Lammers T, Rizzo LY, Storm G, Kiessling F (2012) Personalized nanomedicine. Clin Cancer Res 18(18):4889–4894
Lanza GM, Moonen C, Baker JR Jr, Chang E, Cheng Z, Grodzinski P, Ferrara K et al (2014) Assessing the barriers to image-guided drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 6(1):1–14
Lee H, Lee E, Kim DK, Jang NK, Jeong YY, Jon S (2006) Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J Am Chem Soc 128(22):7383–7389
Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM et al (2014) Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood 124(21):291
Liebmann JE et al (1993) Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 68:1104–1109
Lishmanov IuB, Chernov VI, Krivonogov NG, Glukhov GG, Maslova LV (1988) Experimental perfusion scintigraphy of the myocardium using Tl-199 chloride. Med Radiol (Mosk) 33(3):13–16
Liu D, Huang X, Wang Z, Jin A, Sun X, Zhu L (2013) Gold nanoparticle-based activatable probe for sensing ultralow levels of prostatespecific antigen. ACS Nano 7:5568–5576
Liu Y, Li LL, Qi GB, Chen XG, Wang H (2014) Dynamic disordering of liposomal cocktails and the spatio-temporal favorable release of cargoes to circumvent drug resistance. Biomaterials 35:3406–3415
Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM (2008) Radiation-induced IFN- production within the tumor microenvironment influences antitumor immunity. J Immunol 180(5):3132–3139
MacFarlane AW, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E et al (2014) PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res 2(4):320–331
Maruyama T, Mimura K, Sato E, Watanabe M, Mizukami Y, Kawaguchi Y, Ando T et al (2010) Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma. Br J Cancer 103(4):552–559
Masson E, Zamboni WC (1997) Pharmacokinetic optimisation of cancer chemotherapy. Effect Outcomes Clin Pharmacokinet 32(4):324–343
Miao Y, Figueroa SD, Fisher DR, Moore HA, Testa RF, Hoffman TJ, Quinn TP (2008) 203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med 49(5):823–829
Mimura K, Ando T, Poschke I, Mougiakakos D, Johansson CC, Ichikawa J, Okita R et al (2011) T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer 128(2):390–401
Natfji AA, Ravishankar D, Osborn HMI, Greco F (2017) Parameters affecting the enhanced permeability and retention effect: the need for patient selection. J Pharm Sci 106(11):3179–3187
Nguyen KT (2011) Targeted nanoparticles for cancer therapy: promises and challenges. J Nanomed Nanotechnol 34:45–51
Ojha T, Rizzo L, Storm G, Kiessling F, Lammers T (2015) Image-guided drug delivery: preclinical applications and clinical translation. Expert Opin Drug Deliv 12(8):1203–1207
Park K, Lee S, Kang E, Kim K, Choi K, Kwon IC (2009) New generation of multifunctional nanoparticles for cancer imaging and therapy. Adv Funct Mater 19(10):1553–1566
Pathirana AA, Vinjamuri S, Byrne C, Ghaneh P, Vora J, Poston GJ (2001) (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. Eur J Surg Oncol 27(4):404–408
Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA et al (2008) Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 14(3):797–803
Podojil JR, Miller SD (2009) Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol Rev 229(1):337–355
Popovtzer R, Agrawal A, Kotov NA, Popovtzer A, Balter J, Carey TE, Kopelman R (2008) Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett 8(12):4593–4596
Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST et al (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73(8):2412–2417
Raymond E et al (1997) Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units. Anticancer Drugs 8:379–385
Ratain MJ, Plunkett WK Jr (2003) Principles of pharmacokinetics. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF et al (eds.). Holland-frei cancer medicine. 6th edn. Hamilton (ON): BC Decker. https://www.ncbi.nlm.nih.gov/books/NBK12815/
Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K et al (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203(5):1259–1271
Rivadeneira DB, Delgoffe GM (2018) Antitumor T cell reconditioning: improving metabolic fitness for optimal cancer immunotherapy. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-17-0894
Rodichev A, Garbuzov P, Drozdovsky B, Krylov V, Guseva T, Davydov G, Parshin V et al (2009) Vestnik RONC im NN Blohina RAMN 20(2):19–20
Rogov A, Skuridin V, Stasyuk E, Nesterov E, Ilina E, Sadkin V, Chernov V et al (2015) Clinical significance of sentinel lymph node detection in patients with invasive cervical cancer. Eur J Nucl Med Mol Imaging 42(1):856
Sachdeva M, Fischl MA, Pahwa R, Sachdeva N, Pahwa S (2010) Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients. J Acquir Immune Defic Syndr 54(5):447–454
Sharma A, Bode B, Studer G, Moch H, Okoniewski M, Knuth A, von Boehmer L et al (2013) Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. Clin Cancer Res 19(17):4843–4853
Shiryaev SV, Odzharova AA, Orel NF, Podluzhny DV, Polyakov AN, Rabinovich EZ, Volkov RJ (2008) Med Radiol Radiat Saf 53(1):53–62
Siqing F, Culotta K, Falchook G, Hong D, Myers A, Zhang Y, Naing A, Janku F, Hou M, Kurzrock R (2016) Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol 77(2):357–364
Skuridin V, Stasyuk E, Bragina O, Usubov M, Chernov V, Larkina M, Zelchan R et al (2016) Eur J Nucl Med Mol Imaging 43(1):465
Svensson M, Stockinger B, Wick MJ (1997) Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. J Immunol 158(9):4229–4236
Tartis M. (2009) Nanotechnology in nuclear medicine. The University of New Mexico Health Sciences Center College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Program No. 039-000-09-147-H04-P 3.0.
Toon S (1996) The relevance of pharmacokinetics in the development of biotechnology products. Eur J Drug Metab Pharmacokinet 21(2):93–103
Vasir JK, Labhasetwar V (2007) Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev 59(8):718–728
Vural Uçmak G, Özer AY (2015) Nükleer Tıpta İlaç Taşıyıcı Sistemler ve Teranostik Kullanımları. Nucl Med Semin 2:109–119
Wen CJ, Zhang LW, Al-Suwayeh SA, Yen TC, Fang JY (2012) Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int J Nanomed 7:1599–1611
Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, Falandry C et al (2014) International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32(24):2595–2603
Xin Y, Yin M, Zhao L, Meng F, Luo L (2017) Recent progress on nanoparticle-based drug delivery systems for cancer therapy. Cancer Biol Med 14(3):228–241
Yang W, Cheng Y, Xu T, Wang X, Wen LP (2009) Targeting cancer cells with biotin-dendrimer conjugates. Eur J Med Chem 44(2):862–868
Yingchoncharoen P, Kalinowski DS, Richardson DR, Barker EL (2016) Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev 68:3
Yu MK, Park J, Jon S (2012) Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2(1):3–44
Zeltchan R, Chernov V, Medvedeva A, Sinilkin I, Stasyuk E, Rogov A, Il’ina E et al (2016a) Study of a glucose derivative labeled with technetium-99m as potential radiopharmaceutical for cancer. Eur J Nucl Med Mol Imaging 43(Suppl 1):466
Zeltchan R, Medvedeva A, Sinilkin I, Bragina O, Chernov V, Stasyuk E, Rogov A et al (2016b) Experimental study of radiopharmaceuticals based on technetium-99m labeled derivative of glucose for tumor diagnosis. IOP Conf Mater Sci Eng 135:012054
Zuo M, Shen H, Yin J, Wang W, Zhang Y, Zhou DB, Zhang W (2018) Expression of PD-1 on peripheral blood Treg cells is related to the diagnosis, prognosis and treatment of T cell non-Hodgkin lymphoma. Leuk Res 70:56–61
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of human and animal rights
This article does not contain any studies with human and animal subjects performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Atlihan-Gundogdu, E., Ilem-Ozdemir, D., Ekinci, M. et al. Recent developments in cancer therapy and diagnosis. J. Pharm. Investig. 50, 349–361 (2020). https://doi.org/10.1007/s40005-020-00473-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40005-020-00473-0